Effective use method of medicaments and method of preventing...

Details Effective use method of medicaments and method of preventing... Effective use method of medicaments and method of preventing...

2009-12-31

2010-10-05

Davis, Brian J (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S341000, C564S346000, C564S348000, C564S351000, C564S360000, C564S374000, C546S334000, C514S357000, C514S651000, C514S653000

Reexamination Certificate

active

07807854

ABSTRACT:
To provide a medicament which efficiently expresses an immunosuppressive agent or an anti-inflammatory agent and reduces expression of side effect.A medicament includes diaryl sulfide or diaryl ether compound having a 2-amino-1,3-propanediol structure having an activity of reducing lymphocytes circulating peripherally, in combination with an immunosuppressive agent and/or an anti-inflammatory agent.

REFERENCES:
patent: 5447922 (1995-09-01), Lawrence et al.
patent: 5604229 (1997-02-01), Fujita et al.
patent: 5948820 (1999-09-01), Fujita et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6214873 (2001-04-01), Adachi et al.
patent: 6489331 (2002-12-01), Shimada et al.
patent: 6960692 (2005-11-01), Kohno et al.
patent: 6963012 (2005-11-01), Kohno et al.
patent: 7456157 (2008-11-01), Kohno et al.
patent: 7482491 (2009-01-01), Kohno et al.
patent: 2002/0040050 (2002-04-01), Xu et al.
patent: 2002/0091105 (2002-07-01), Mandala et al.
patent: 2002/0143034 (2002-10-01), Taniguchi et al.
patent: 2003/0236297 (2003-12-01), Nishi et al.
patent: 2004/0058894 (2004-03-01), Doherty et al.
patent: 2004/0067908 (2004-04-01), Nakade et al.
patent: 2004/0087662 (2004-05-01), Bigaud et al.
patent: 2004/0110728 (2004-06-01), Macdonald et al.
patent: 2004/0138462 (2004-07-01), Sakurai et al.
patent: 2004/0147490 (2004-07-01), Albert et al.
patent: 2004/0224941 (2004-11-01), Seko et al.
patent: 2004/0235794 (2004-11-01), Nakade et al.
patent: 2004/0242654 (2004-12-01), Kohno et al.
patent: 2004/0248952 (2004-12-01), Pan et al.
patent: 2004/0254222 (2004-12-01), Kohno et al.
patent: 2005/0009786 (2005-01-01), Pan et al.
patent: 2005/0020837 (2005-01-01), Doherty et al.
patent: 2005/0033055 (2005-02-01), Bugianesi et al.
patent: 2005/0043386 (2005-02-01), Nishi et al.
patent: 2005/0107345 (2005-05-01), Doherty et al.
patent: 2005/0222422 (2005-10-01), Lynch et al.
patent: 2005/0245575 (2005-11-01), Chen et al.
patent: 2006/0046979 (2006-03-01), Foster et al.
patent: 2006/0089334 (2006-04-01), Budhu et al.
patent: 2006/0135622 (2006-06-01), Kohno et al.
patent: 2006/0135786 (2006-06-01), Saha et al.
patent: 2006/0148830 (2006-07-01), Terakado et al.
patent: 2006/0148844 (2006-07-01), Nakade et al.
patent: 2006/0160771 (2006-07-01), Kohno et al.
patent: 2006/0161005 (2006-07-01), Doherty et al.
patent: 2006/0166940 (2006-07-01), Buehlmayer et al.
patent: 2006/0211656 (2006-09-01), Albert et al.
patent: 2006/0211658 (2006-09-01), Hinterding et al.
patent: 2006/0252741 (2006-11-01), Colandrea et al.
patent: 2006/0264403 (2006-11-01), Albert
patent: 2007/0010494 (2007-01-01), Ehrhardt et al.
patent: 2007/0043014 (2007-02-01), Doherty et al.
patent: 2007/0088002 (2007-04-01), Lynch et al.
patent: 2007/0135501 (2007-06-01), Hinterding et al.
patent: 2007/0149597 (2007-06-01), Nishi et al.
patent: 2007/0167410 (2007-07-01), Pan et al.
patent: 2007/0167425 (2007-07-01), Nakade et al.
patent: 2007/0191468 (2007-08-01), Nishi et al.
patent: 2007/0203100 (2007-08-01), Pan et al.
patent: 2007/0225260 (2007-09-01), Hinterding et al.
patent: 2008/0025973 (2008-01-01), Fleenor et al.
patent: 2008/0027508 (2008-01-01), Chu
patent: 2008/0032923 (2008-02-01), Kudou et al.
patent: 2008/0153882 (2008-06-01), Nishi et al.
patent: 2008/0161410 (2008-07-01), Kusters et al.
patent: 2008/0200438 (2008-08-01), Albert et al.
patent: 2008/0207584 (2008-08-01), Habashita et al.
patent: 2008/0207941 (2008-08-01), Tsubuki et al.
patent: 2008/0249093 (2008-10-01), Colandrea et al.
patent: 2009/0023797 (2009-01-01), Azzaoui et al.
patent: 11-080026 (1999-03-01), None
patent: 2002-53575 (2002-02-01), None
patent: 2002-316985 (2002-10-01), None
patent: 2003-137894 (2003-05-01), None
patent: 2003-267936 (2003-09-01), None
patent: 2004-137208 (2004-05-01), None
patent: 2004-307439 (2004-11-01), None
patent: 2004-307440 (2004-11-01), None
patent: 2004-307441 (2004-11-01), None
patent: 2004-307442 (2004-11-01), None
patent: 2005-47899 (2005-02-01), None
patent: 2005-247691 (2005-09-01), None
patent: 01/98301 (2001-12-01), None
patent: 02/067915 (2002-09-01), None
patent: 02/100148 (2002-12-01), None
patent: 03/029184 (2003-04-01), None
patent: 03/029205 (2003-04-01), None
patent: 2005/014525 (2005-02-01), None
patent: 2005/014603 (2005-02-01), None
patent: 2005/063671 (2005-07-01), None
patent: 2006/041015 (2006-04-01), None
patent: 2006/063033 (2006-06-01), None
patent: 2006/129688 (2006-12-01), None
patent: 2007/043433 (2007-04-01), None
patent: 2007/043568 (2007-04-01), None
patent: 2007/091501 (2007-08-01), None
Blam et al., Integrating Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Current and Future Perspectives, Am. J. Gastroenterology, 2001, vol. 96, No. 7, pp. 1977-1997.
Keller et al., Immunomodulator FTY720 Induces Myofibroblast Differentiation via the Lysophospholipid Receptor S1P3 and Smad3 Signaling, Am. J. Pathology, Jan. 2007, vol. 170, No. 1, pp. 281-292.
Yasuyuki Igarashi, Sphingosine-1-Phosphate as an Intercellular Signaling Molecule, Ann. NY Acad. Sci., 1998, vol. 845, pp. 19-31.
Jacobs et al., Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis, Ann. Neurol., 1996, vol. 39, No. 3, pp. 285-294.
Weinshenker et al., A Randomized Trial of Plasma Exchange in Acute Central Nervous System Inflammatory Demyelinating Disease, Ann. Neurol., 1999, vol. 46, No. 6, pp. 878-886.
Ganem et al., The Molecular Biology of the Hepatitis B Virus, Annu. Rev. Biochem., 1987, vol. 56 pp. 651-693.
Kaneko et al., Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice, Biochem. and Biophys. Res. Commun., 2006, vol. 345, pp. 85-92.
Okazaki et al., Molecular Cloning of a Novel Putative G Protein-Coupled Receptor Expressed in the Cardiovascular System, Biochem. and Biophys. Res. Commun., 1993, vol. 190, No. 3, pp. 1104-1106.
Klein et al., Total Synthesis and Antifungal Evaluation of Cyclic Aminohexapeptides, Bioorg. Med. Chem., 2000, vol. 8, pp. 167-1696.
Hashimoto et al., β-Phenylselenoalanine as a dehydroalanine precursor-efficient synthesis of alternariolide (AM-toxin I), Chem. Commun., 1996, pp. 1139-1140.
Levkau et al., High-Density Lipoprotein Stimulates Myocardial Perfusion in Vivo, Circulation, 2004, vol. 110, pp. 3355-3359.
Salomone et al., S1P3receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate, Eur. J. Pharmacol., 2003, vol. 469, pp. 125-134.
Heneghan et al., Current and Novel Immunosuppressive Therapy for Autoimmune Hepatitis, Hepatology, 2002, vol. 35, No. 1, pp. 7-13.
Francis V. Chisari, Cytotoxic T Cells and Viral Hepatitis, J. Clin. Invest., Apr. 1997, vol. 99, No. 7, pp. 1472-1477.
Kiuchi et al., Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols, J. Med. Chem., 2000, vol. 43, pp. 2946-2961.
Brinkmann et al., The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors, J. Biol. Chem., 2002, vol. 277, No. 24, pp. 21453-21457.
Sanna et al., Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate, J. Biol. Chem., Apr. 2, 2004, vol. 279, No. 14, pp. 13839-13848.
Forrest et al., Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents are Mediated via Distinct Receptor Subtypes, J. Pharm. Exp. Ther., 2004, vol. 309, No. 2, pp. 758-768.
George C. Ebers, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, Lancet, Nov. 7, 1998, vol. 352, pp. 1498-1501.
Takuwa et al., Subtype-specific, differential activities of the EDG family receptors for sphingosine-1-phosphate, a novel lysophospholipid mediator, Mol. Cell. Endocrinol., 2001, vol. 177, pp. 3-11.
Fried et al., Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection, N. Engl. J. Med., Sep. 26, 2002, vol. 347, No. 13, pp. 975-982.
Mailliard et al., Suppressing Hepatitis B without Resistance—So Far, So Good, N. Engl. J. Med., Feb. 27, 2003, vol. 348, No. 9, pp. 848-850.
Niessen

Affiliated with

Also associated with

Rating

Effective use method of medicaments and method of preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Effective use method of medicaments and method of preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Effective use method of medicaments and method of preventing... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4211659